The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Receipt of £1m deferred consideration

19 Dec 2016 11:37

RNS Number : 2467S
Premier Veterinary Group PLC
19 December 2016
 

 

PREMIER VETERINARY GROUP plc

("PVG" or "the Company")

 

 

Receipt of £1m deferred consideration

 

 

 

London, UK, 19 December 2016 - Premier Veterinary Group plc (LSE: PVG) provides the following update:

 

As reported in the preliminary results announcement on 29 November 2016, the Group's statement of financial position as at 30 September 2016 contained an amount of £1m receivable which related to deferred consideration for the sale of its veterinary practices in December 2015. This amount had been held in escrow to cover potential liabilities under warranty and indemnity provisions in the sale and purchase agreement. The full value of the £1m escrow balance has now been received, in line with directors' expectations. 

The Annual Report and Accounts for the year ended 30 September 2016 (the "Annual Report") will be posted to shareholders by the end of December, together with the Notice of Annual General Meeting which is to be held at 11.30 am on 3 March 2017 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH. A full copy of the Annual Report (incorporating the Notice of Annual General Meeting) is also available on the Company's website at www.premiervetgroup.co.uk within the Investor Relations section.

 

For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

 

Dominic Tonner, Chief Executive Officer

Will Evans, Chief Financial Officer

 

Square1 Consulting Tel: +44 (0)207 929 5599

 

David Bick/Brian Alexander

 

 

 

Note to Editors:

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare program for pets branded "Premier Pet Care Plan" ("PPCP"); and the operation of a buying group (the "PVA Buying Group") which offers enhanced discounts to member practices on pharmaceutical and consumable spending. In the US, Premier Pet Care Plan is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare program for cats, dogs and rabbits and is available only through veterinary practices. The program is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice, which has been proven to work extremely well. PVA works alongside practices to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice performance.

 

The PVA Buying Group, is now the UK's largest veterinary buying group without group interests in veterinary practices or veterinary wholesalers offering its members the best discounts across the industry on pharmaceutical and consumable spend.

 

For further details: http://www.premiervetalliance.co.uk/: 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward- looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKLFFQLFXFBE
Date   Source Headline
14th Apr 20102:09 pmRNSRule 8.3- Ark Therapeutics Group PLC
14th Apr 201011:41 amRNSEPT Disclosure-Amendment
13th Apr 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
13th Apr 201011:34 amRNSEPT Disclosure
13th Apr 201011:31 amRNSRule 8.3- ARK THERAPEUTICS
13th Apr 201011:29 amRNSEPT Disclosure
12th Apr 201011:22 amRNSEPT Disclosure
12th Apr 201010:19 amRNSEPT Disclosure
12th Apr 20107:00 amRNSResearch Update
9th Apr 201011:35 amRNSEPT Disclosure
9th Apr 201011:33 amRNSEPT Disclosure- Amendment
9th Apr 20109:28 amRNSEPT Disclosure
8th Apr 20102:43 pmRNSEPT Disclosure-Amendment
8th Apr 201012:27 pmRNSEPT Disclosure
8th Apr 201010:43 amRNSRule 8.3- ARK THERAPEUTICS
8th Apr 20108:33 amRNSEPT Disclosure
7th Apr 20104:08 pmRNSAnnual Information Update
7th Apr 201010:59 amRNSRule 8.3- ARK THERAPEUTICS
1st Apr 201011:03 amRNSArk Therapeutics Group plc
1st Apr 201011:00 amRNSEPT Disclosure
1st Apr 201010:37 amRNSEPT Disclosure
31st Mar 20103:42 pmRNSTotal Voting Rights
31st Mar 20102:00 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
31st Mar 201010:37 amRNSEPT Disclosure
30th Mar 201012:48 pmRNSEPT Disclosure
30th Mar 201012:42 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201012:08 pmBUSRule 8.3 - Ark Therapeutics Group plc
25th Mar 201010:53 amRNSEPT Disclosure
24th Mar 201011:52 amRNSEPT Disclosure
24th Mar 201011:15 amRNSEPT Disclosure
24th Mar 201010:25 amBUSRule 8.3 - Ark Therapeutics Group plc
22nd Mar 20101:48 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:42 pmRNSRule 8.3- ARK THERAPEUTICS GROUP PLC
22nd Mar 20101:24 pmBUSRule 8.3 - ARK THERAPEUTICS GROUP PLC
22nd Mar 201011:45 amRNSEPT Disclosure
22nd Mar 201010:18 amRNSEPT Disclosure
19th Mar 20104:58 pmRNSRule 8.3- (Ark Therapeutics Group Plc)
19th Mar 20102:56 pmRNSRule 8.3- Ark Therapeutics Group plc
19th Mar 20101:30 pmBUSRule 8.3 - Ark Therapeutics Group plc
19th Mar 201011:45 amRNSEPT Disclosure
19th Mar 201010:30 amRNSEPT Disclosure
18th Mar 201012:14 pmRNSEPT Disclosure
17th Mar 201010:38 amRNSEPT Disclosure
16th Mar 20103:55 pmRNSHolding(s) in Company
16th Mar 201011:12 amRNSEPT Disclosure
15th Mar 201011:30 amRNSEPT Disclosure
15th Mar 201010:34 amRNSEPT Disclosure
11th Mar 201011:49 amRNSEPT Disclosure
10th Mar 20104:40 pmRNSSecond Price Monitoring Extn
10th Mar 20104:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.